Overview
If Meiji Holdings gets glum over weak candy sales, it's got plenty of antidepressants handy. The company is a leading Japanese confectioner and maker of milk and dairy products. Meiji-brand sweets include chocolate and non-chocolate candy and chewing gum, along with personal care products, such as throat gargle. Its pharmaceutical division offers antibiotics, generic drugs, and anti-anxiety medications for humans, as well as veterinary drugs. The
...
Read More Group has two operating segments: Food segment run by Meiji Co. Ltd and Pharmaceutical segment is run by Meiji Seika Pharma Co., Ltd. and KM Biologics Co., Ltd. Its Food segment accounts for nearly 85% of total sales. The Group has around 65 companies worldwide focusing its operations in Japan.
Read Less
Read More Group has two operating segments: Food segment run by Meiji Co. Ltd and Pharmaceutical segment is run by Meiji Seika Pharma Co., Ltd. and KM Biologics Co., Ltd. Its Food segment accounts for nearly 85% of total sales. The Group has around 65 companies worldwide focusing its operations in Japan.
Read Less
KATSUNARI MATSUDA
See more contacts
Management of Companies and Enterprises
,
Holding companies, nec
?
?
?
Actual
?
Actual
$7.41 billion
Actual
4.08%
-27.01%
$1.21 million
MAR
?
?
Tokyo:2269
Contacts
Get in Touch with 12 Principals*
-
KATSUNARI MATSUDAPresident
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of March 31, 2025 (12 month period) in USD
Annual Revenue 2024
$7.41 billion
USD
Actual
1 USD = 149.1202 JPY
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | $724 | $570 | $855 |
| Net Investing Cash | -$165 | -$247 | -$185 |
| Net Financing Cash | -$294 | -$367 | -$516 |
| Net Change in Cash | $266 | -$44 | $154 |
| Cash at Beginning of Period | $409 | $435 | $262 |
| Cash at End of Period | $690 | $409 | $435 |
| Capital Expenditure | -$358 | -$484 | -$625 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $717 | $426 | $452 |
| Accounts Receivable | $1,356 | $1,160 | $1,167 |
| Inventories | $1,337 | $1,338 | $1,241 |
| Other Current Assets | $366 | $234 | $196 |
| Asset Summary | |||
| Total Current Assets | $3,776 | $3,158 | $3,055 |
| Tangible Fixed Assets | $3,222 | $3,271 | $3,242 |
| Intangible Assets | $ | $ | $122 |
| Total Assets | $1,205,288 | $1,136,217 | $1,117,459 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $854 | $753 | $722 |
| Short-Term Debt | $150 | $100 | $189 |
| Other Current Liabilities | $1,158 | $933 | $1,012 |
| Liability Summary | |||
| Total Current Liabilities | $2,162 | $1,786 | $1,923 |
| Long-Term Debt | $185 | $332 | $356 |
| Other Long-Term Liabilities | $56 | $49 | $30 |
| Total Liabilities | $2,800 | $2,581 | $2,712 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $201 | $201 | $201 |
| Retained Earnings | $4,199 | $4,037 | $3,757 |
| Equity Summary | |||
| Total Equity | $5,006 | $4,774 | $4,515 |
| Shares Outstanding | 279,106,362 | 278,781,000 | 281,643,000 |